International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 2 , Pages 392-398 , 1 June 2009

Phase I–II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer

  • Nadia Di Muzio, M.D.

      Affiliations

    • Department of Radiotherapy, Scientific Institute San Raffaele, Milan, Italy
    • Corresponding Author InformationReprint requests to: Nadia Di Muzio, M.D., Radiotherapy Department, Scientific Institute San Raffaele, via Olgettina 60, 20132 Milan; Tel: (+39) 02-26437643; Fax: (+39) 02-26437639
    • ,
  • Claudio Fiorino, Ph.D.

      Affiliations

    • Department of Medical Physics, Scientific Institute San Raffaele, Milan, Italy
    • ,
  • Cesare Cozzarini, M.D.

      Affiliations

    • Department of Radiotherapy, Scientific Institute San Raffaele, Milan, Italy
    • ,
  • Filippo Alongi, M.D.

      Affiliations

    • Department of Radiotherapy, Scientific Institute San Raffaele, Milan, Italy
    • ,
  • Sara Broggi, Ph.D.

      Affiliations

    • Department of Medical Physics, Scientific Institute San Raffaele, Milan, Italy
    • ,
  • Paola Mangili, Ph.D.

      Affiliations

    • Department of Medical Physics, Scientific Institute San Raffaele, Milan, Italy
    • ,
  • Giorgio Guazzoni, M.D.

      Affiliations

    • Department of Urology, Scientific Institute San Raffaele, Milan, Italy
    • ,
  • Riccardo Valdagni, M.D.

      Affiliations

    • Prostate Program—Scientific Direction, National Institute of Tumours, Milan, Italy
    • ,
  • Riccardo Calandrino, Ph.D.

      Affiliations

    • Department of Medical Physics, Scientific Institute San Raffaele, Milan, Italy
    • ,
  • Ferruccio Fazio, M.D.

      Affiliations

    • Department of Radiotherapy, Scientific Institute San Raffaele, Milan, Italy
    • Nuclear Medicine, Scientific Institute San Raffaele, Milan, Italy
    • IBFM-CNR, Milan, Italy

Received 28 May 2008 ,Revised 7 August 2008 ,Accepted 7 August 2008.

References 

  1. Pollack A, Smith LG, Von Eschenbach AC. External beam radiotherapy dose response characteristics of 1,127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 2000;48:507–512
  2. Zietman AL, Desilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239
  3. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose Phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  4. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose–response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomize Phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006;24:1990–1996
  5. Brenner DJ, Marinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  6. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  7. Brenner DJ. Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:315–316
  8. Fowler JF, Chappell R, Ritter M. Is α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  9. Logue JP, Cowan RA, Hendry JH. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:1522
  10. Fowler JF, Chappell RJ, Ritter MA. The prospects for new treatments for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:3–5
  11. Nahum AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;572:391–401
  12. Yan D, Lockman D, Brabbins D, et al. An off-line strategy for constructing a patient-specific planning target volume in adaptive treatment process for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:289–302
  13. Wong JR, Grimm L, Uematsu M, et al. Image-guided radiotherapy for prostate cancer by CT-linear accelerator combination: Prostate movements and dosimetric consideration. Int J Radiat Oncol Biol Phys. 2005;61:561–569
  14. Roach M, De Silvio C, Lawton CA, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  15. Lawton CA, De Silvio M, Roach M, et al. An update of the Phase III trial comparing whole-pelvic (WP) to prostate-only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): Update analysis of RTOG94-13. Proceedings of 47th annual ASTRO Meeting. Denver, CO, October 16–20, 2005. p. 519.
  16. Mackie TR, Kapatoes J, Ruchala K, et al. Image guidance for precise conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:89–105
  17. Grigorov G, Kron T, Wong E, et al. Optimization of helical tomotherapy treatment plans for prostate cancer. Phys Med Biol. 2003;48:1933–1943
  18. Shepard DM, Olivera GH, Reckwerdt PJ, et al. Iterative approaches to dose optimisation in tomotherapy. Phys Med Biol. 2000;45:69–90
  19. Fiorino C, Cozzarini C, Vavassori V, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: Analysis of a large group of patients pooled from three institutions. Radiother Oncol. 2002;64:1–12
  20. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose–volume constraints in high-dose conformal radiotherapy for localized prostate cancer. J Radiat Oncol Biol Phys. 2003;57:953–962
  21. Fiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3DCRT for localized prostate cancer: Preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008;70:1130–1137
  22. Fiorino C, Di Muzio N, Broggi S, et al. Evidence of limited motion of the prostate by careful emptying of the rectum as assessed by daily MVCT image-guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys. 2008;7:611–617
  23. Keiler L, Dobbins D, Kulasekere R, et al. Tomotherapy for prostate adenocarcinoma: A report on acute toxicity. Radiother Oncol. 2007;84:171–176
  24. Soete G, Arcangeli S, De Meerleer G, et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity. Radiother Oncol. 2006;80:78–81
  25. Junius S, Haustermans K, Bussels B, et al. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a Phase I/II feasibility study. Radiat Oncol. 2007;2:29
  26. Vavassori V, Fiorino C, Rancati T, et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2007;66:1401–1410
  27. Peeters ST, Hoogeman MS, Heemsbergen WD, et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  28. Valdagni R, Rancati T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3DCRT. Int J Radiat Oncol Biol Phys. 2008;71:1065–1073
  29. Fiorino C, Alongi F, Broggi S, et al. Physics aspects of prostate tomotherapy: Planning optimization and image-guidance issues. Acta Oncol. 2008;47:1309–1316
  30. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  31. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2007;69:1084–1089
  32. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose-escalation trial. Int J Radiat Oncol Biol Phys. 2006;64:518–526
  33. Muren LP, Wasbø Helle SI, et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences. Int J Radiat Oncol Biol Phys. 2008;71:1034–1041
  34. Arcangeli S, Saracino B, Petrongari MG, et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol. 2007;84:148–155
  35. Cozzarini C, Fiorno C, Di Muzio N, et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol. 2007;84:164–170

 Conflict of interest: none.

PII: S0360-3016(08)03397-X

doi: 10.1016/j.ijrobp.2008.08.038

International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 2 , Pages 392-398 , 1 June 2009

Article Tools

* Image Usage & Resolution